832 related articles for article (PubMed ID: 26372466)
1. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
2. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
4. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.
Yun Kirby S; Zhu CQ; Kerwin EM; Stanford RH; Georges G
COPD; 2016; 13(2):167-75. PubMed ID: 26516724
[TBL] [Abstract][Full Text] [Related]
5. The Ellipta
Jones TL; Neville DM; Chauhan AJ
Ther Deliv; 2018 Feb; 9(3):169-176. PubMed ID: 29424288
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
7. Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
Svedsater H; Dale P; Garrill K; Walker R; Woepse MW
BMC Pulm Med; 2013 Dec; 13():72. PubMed ID: 24314123
[TBL] [Abstract][Full Text] [Related]
8. Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.
Komase Y; Asako A; Kobayashi A; Sharma R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1365-75. PubMed ID: 25525354
[TBL] [Abstract][Full Text] [Related]
9. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD.
van der Palen J; Moeskops-van Beurden W; Dawson CM; James WY; Preece A; Midwinter D; Barnes N; Sharma R
Int J Chron Obstruct Pulmon Dis; 2018; 13():2515-2523. PubMed ID: 30174421
[TBL] [Abstract][Full Text] [Related]
11. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
12. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study.
Zervas E; Samitas K; Gaga M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287
[TBL] [Abstract][Full Text] [Related]
13. Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.
Riley JH; Tabberer M; Richard N; Donald A; Church A; Harris SS
Int J Chron Obstruct Pulmon Dis; 2016; 11():1873-80. PubMed ID: 27578968
[TBL] [Abstract][Full Text] [Related]
14. An Acoustic-Based Method to Detect and Quantify the Effect of Exhalation into a Dry Powder Inhaler.
Holmes MS; Seheult JN; O'Connell P; D'Arcy S; Ehrhardt C; Healy AM; Costello RW; Reilly RB
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):247-53. PubMed ID: 25393346
[TBL] [Abstract][Full Text] [Related]
15. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
[TBL] [Abstract][Full Text] [Related]
16. Influence of inhaler technique on asthma and COPD control: a multicenter experience.
Dudvarski Ilic A; Zugic V; Zvezdin B; Kopitovic I; Cekerevac I; Cupurdija V; Perhoc N; Veljkovic V; Barac A
Int J Chron Obstruct Pulmon Dis; 2016; 11():2509-2517. PubMed ID: 27785007
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey.
Price D; Keininger DL; Viswanad B; Gasser M; Walda S; Gutzwiller FS
Int J Chron Obstruct Pulmon Dis; 2018; 13():695-702. PubMed ID: 29520137
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Comparison of a Unit Dose Dry Powder Inhaler with a Multidose Dry Powder Inhaler for Delivery of Fluticasone Furoate.
Mehta R; Moore A; Riddell K; Joshi S; Chan R
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):332-338. PubMed ID: 28463040
[TBL] [Abstract][Full Text] [Related]
19. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
20. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
